

**DUR Committee Agenda
October 13, 2009**

**Office of MaineCare Services, Department of Health and Human Services
442 Civic Center Drive, Augusta, Maine
1:00 to 8:00 pm**

Call to Order

1:00 pm

Public Comments -Open Session

New Business: Annual PDL Review

- a) **Closed session to discuss financials**
- b) **Open session to review and vote categories subject to potential changes:**
 - 1. **Beta lactams- remove Augmentin XR from preferred**
 - 2. **Antiretrovirals- add performance based PA exemptions**
 - 3. **Hepatitis C- remove Peg-Intron from preferred status**
 - 4. **RSV- update criteria based on AAP guideline**
 - 5. **DPP4 Inhibitors- non-prefer Onglyza**
 - 6. **TZDs and related combinations- only Actos 15 mg preferred**
 - 7. **Osteoporosis- remove Fosamax/D from preferred status**
 - 8. **Growth hormones- add Omnitrope to preferred**
 - 9. **Zetia – discuss Zetia splitting w/o PA**
 - 10. **Pulmonary hypertension/ERA- add Letairis to preferred**
 - 11. **Antiemetics- remove Emend from preferred status**
 - 12. **Nasal steroids- remove Veramyst from preferred status**
 - 13. **Inhaled steroids- remove Pulmicort inhaler from preferred status**
 - 14. **Inflammatory Bowel Disease- add Apriso to preferred, Asacol 800 mg HD non-preferred, remove Pentasa 500 mg and Lialda to non-preferred status**
 - 15. **Antidepressants- add Lexapro preferred, Venlafaxine ER preferred (replacing all Effexor XR scripts), and Savella preferred for fibromyalgia**
 - 16. **Alzheimer’s- remove Exelon to non-preferred, discuss value of class**
 - 17. **Narcotics long acting- add Kadian (except 80mg and 200 mg doses) preferred**
 - 18. **Biologicals- limit Enbrel to only 25 mg vials**
 - 19. **Migraine- remove Relpax and Treximet to non-preferred leaving sumatriptan and Maxalt MLT as preferred triptans**
 - 20. **Anticonvulsants- add Trileptal suspension to preferred**
 - 21. **Topical Antibiotics- remove Altabax to non-preferred status**
 - 22. **Pediculicides- make Ulesfia non-preferred, discuss malathion**
 - 23. **LHRH Analogs- Firmagon non-preferred to confirm indication/ first line LHRHA failure)**

Other Business:

- 1. **WIC Medicaid formula coverage update**
- 2. **Chronic narcotic use PA/ promotion of standard of care update**
- 3. **Discuss other pharmacy savings initiatives (closed)**

Adjournment

8:00 pm

